{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:58:11Z","timestamp":1790402291084,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T00:00:00Z","timestamp":1534550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s12022-018-9540-9","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T06:54:52Z","timestamp":1534575292000},"page":"317-323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis"],"prefix":"10.1007","volume":"29","author":[{"given":"Daniel","family":"Lubin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Baraban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Lisby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Jalali-Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Livolsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,18]]},"reference":[{"issue":"13","key":"9540_CR1","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","volume":"317","author":"H Lim","year":"2017","unstructured":"Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM (2017) Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. Jama 317(13):1338, 1348.","journal-title":"Jama"},{"issue":"6","key":"9540_CR2","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1067\/msy.2099.101431","volume":"126","author":"B Singh","year":"1999","unstructured":"Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP (1999) Coexistent Hashimoto\u2019s thyroiditis with papillary thyroid carcinoma: Impact on presentation, management, and outcome. Surgery 126(6):1070\u20131077.","journal-title":"Surgery"},{"key":"9540_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jso.23967","volume":"1","author":"FH Liu","year":"2015","unstructured":"Liu FH, Kuo SF, Hsueh C, Chao TC, Lin JD (2015) Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. J Surg Oncol 1:149\u2013154.","journal-title":"J Surg Oncol"},{"issue":"8","key":"9540_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00268-002-6612-1","volume":"26","author":"ID Hay","year":"2002","unstructured":"Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26(8):879\u2013885.","journal-title":"World J Surg"},{"issue":"11","key":"9540_CR5","first-page":"1","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21(11):1\u201323.","journal-title":"Trends Mol Med"},{"issue":"11","key":"9540_CR6","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MWL Teng","year":"2015","unstructured":"Teng MWL, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers basedon T-cell infiltration and PD-L1. Cancer Res 75(11):2139\u20132145.","journal-title":"Cancer Res"},{"issue":"1","key":"9540_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/PPO.0000000000000296","volume":"24","author":"DY Wang","year":"2018","unstructured":"Wang DY, Johnson DB, Davis EJ (2018) Toxicities Associated With PD-1\/PD-L1 Blockade. Cancer J 24(1):36\u201340.","journal-title":"Cancer J"},{"issue":"2","key":"9540_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1346-8138.13520","volume":"44","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, Maruyama H, Fujisawa Y, Matsuya T, Fujimoto M, Yamamoto A (2017) Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J Dermatol 44(2):117\u2013122.","journal-title":"J Dermatol"},{"issue":"August 2017","key":"9540_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","volume":"115","author":"K Sato","year":"2018","unstructured":"Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N (2018) Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115 (August 2017):71\u201374.","journal-title":"Lung Cancer"},{"issue":"22","key":"9540_CR10","doi-asserted-by":"publisher","first-page":"32318","DOI":"10.18632\/oncotarget.8698","volume":"7","author":"S Chowdhury","year":"2016","unstructured":"Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R, Walfish PG (2016) Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget 7(22):32318\u201332328.","journal-title":"Oncotarget"},{"issue":"11","key":"9540_CR11","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TCC, Chiu JW, Tse E, Kwong Y (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12(11):2777\u20132789.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"9540_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00428-015-1786-8","volume":"467","author":"MS Hsieh","year":"2015","unstructured":"Hsieh MS, Chou YH, Yeh SJ, Chang YL (2015) Papillary-cystic pattern is characteristic in mammary analogue secretory carcinomas but is rarely observed in acinic cell carcinomas of the salivary gland. Virchows Arch 467(2):145\u2013153.","journal-title":"Virchows Arch"},{"key":"9540_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ebiom.2017.03.031","volume":"18","author":"G Fu","year":"2017","unstructured":"Fu G, Polyakova O, MacMillan C, Ralhan R, Walfish PG (2017) Programmed Death-Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features. EBioMedicine 18:50\u201355.","journal-title":"EBioMedicine"},{"issue":"2","key":"9540_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-16-0421","volume":"24","author":"S Ahn","year":"2017","unstructured":"Ahn S, Kim TH, Kim SW, Ki CS, Jang HW (2017) Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 24(2):97\u2013106.","journal-title":"Endocr Relat Cancer"},{"key":"9540_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12022-018-9514-y","volume":"29","author":"MW Rosenbaum","year":"2018","unstructured":"Rosenbaum MW, Gigliotti BJ, Pai SI, Parangi S, Wachtel H, Mino-Kenudson M, Gunda V, Faquin WC (2018) PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. Endocr Pathol 29:59\u201367.","journal-title":"Endocr Pathol"},{"issue":"1","key":"9540_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4132\/jptm.2017.07.26","volume":"52","author":"HJ An","year":"2018","unstructured":"An HJ, Ko GH, Lee JH, Lee JS, Kim DC, Yang JW, Kim MH, Kim JP, Jung EJ, Song DH (2018) Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma. J Pathol Transl Med 52(1):9\u201313.","journal-title":"J Pathol Transl Med"},{"key":"9540_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/his.13230","volume":"71","author":"K Zwaenepoel","year":"2017","unstructured":"Zwaenepoel K, Jacobs J., de Meulenaere A., Silence K., Smits E., Siozopoulou V., Hauben E., Rolfo C., Rottey S., Pauwels P. (2017) CD70 and PD-L1 in anaplastic thyroid cancer \u2013 promising targets for immunotherapy. Histopathology 71:357\u2013365.","journal-title":"Histopathology"},{"issue":"10","key":"9540_CR18","doi-asserted-by":"publisher","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","volume":"181","author":"AL Kinter","year":"2008","unstructured":"Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, Fauci AS (2008) The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 181(10):6738\u20136746.","journal-title":"J Immunol"},{"issue":"1","key":"9540_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1530\/ERC-12-0313","volume":"20","author":"LL Cunha","year":"2013","unstructured":"Cunha LL, Marcello MA, Morari EC, Nonogaki S, Conte FF, Gerhard R, Soares FA, Vassallo J, Ward LS (2013) Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocr Relat Cancer 20(1):103\u2013110.","journal-title":"Endocr Relat Cancer"},{"key":"9540_CR20","doi-asserted-by":"crossref","unstructured":"McLaughlin JF, et al. (2014) Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). J Clin Oncol 32(15_suppl):8064.","DOI":"10.1200\/jco.2014.32.15_suppl.8064"},{"issue":"2","key":"9540_CR21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/PAI.0000000000000531","volume":"26","author":"ER Parra","year":"2018","unstructured":"Parra ER, Villalobos P, Mino B, Rodriguez-Canales J (2018) Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 26(2):83\u201393.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"9540_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13000-017-0662-z","volume":"12","author":"Y Bai","year":"2017","unstructured":"Bai Y, et al. (2017) PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. Diagn Pathol 12(1):1\u20138.","journal-title":"Diagn Pathol"},{"issue":"4","key":"9540_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/thy.2016.0228","volume":"27","author":"R Shi","year":"2017","unstructured":"Shi R, Qu N, Luo TX, Xiang J, Liao T, Sun GH, Wang Y, Wang YL, Huang CP, Ji QH (2017) Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence. Thyroid 27(4):537\u2013545.","journal-title":"Thyroid"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12022-018-9540-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-018-9540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-018-9540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T18:55:59Z","timestamp":1661799359000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12022-018-9540-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,18]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["9540"],"URL":"https:\/\/doi.org\/10.1007\/s12022-018-9540-9","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,18]]},"assertion":[{"value":"18 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of Pennsylvania and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}